"10.1371_journal.pone.0139155","plos one","2015-10-13T00:00:00Z","Aurélie Delacrétaz; Martin Preisig; Frederik Vandenberghe; Nuria Saigi Morgui; Lina Quteineh; Eva Choong; Mehdi Gholam-Rezaee; Zoltan Kutalik; Pierre Magistretti; Jean-Michel Aubry; Armin von Gunten; Enrique Castelao; Peter Vollenweider; Gerard Waeber; Philippe Conus; Chin B Eap","Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland; Centre of Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland; Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland; Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland; Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland; Laboratory of Neuroenergetics and Cellular Dynamics, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Division of Psychiatric Specialties, University Hospital of Geneva, Geneva, Switzerland; Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland; Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland; Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, Prilly, Switzerland; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland","Conceived and designed the experiments: CBE. Performed the experiments: AD FV NSM LQ. Analyzed the data: AD ZK EC. Contributed reagents/materials/analysis tools: AD MP FV NSM LQ EC MGR ZK PM JMA AVG EC PV GW PC CBE. Wrote the paper: AD MP MGR CBE.","Drs. Waeber, Vollenweider, and Preisig received two unrestricted grants from GlaxoSmithKline to build the CoLaus and PsyCoLaus cohorts and complete the physical and psychiatric baseline investigations. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","10","Aurélie Delacrétaz","AD",16,TRUE,1,4,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
